Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Similar articles for PubMed (Select 23134392)

1.

Quality-of-life effects of prostate-specific antigen screening.

Nagata M, Tanimoto T, Kami M.

N Engl J Med. 2012 Nov 8;367(19):1861-2; author reply 1862. doi: 10.1056/NEJMc1211071#SA2. No abstract available.

PMID:
23134392
2.

Quality-of-life effects of prostate-specific antigen screening.

Haines IE.

N Engl J Med. 2012 Nov 8;367(19):1861; author reply 1862. doi: 10.1056/NEJMc1211071#SA1. No abstract available.

PMID:
23134391
3.

Quality of life and guidelines for PSA screening.

Sox HC.

N Engl J Med. 2012 Aug 16;367(7):669-71. doi: 10.1056/NEJMe1207165. No abstract available.

PMID:
22894580
4.

The dilemmas of prostate cancer screening.

Hugosson J, Carlsson SV.

Med J Aust. 2013 Jun 3;198(10):528-9. No abstract available.

PMID:
23725256
5.

Screening for prostate cancer remains controversial.

Stark JR, Mucci L, Rothman KJ, Adami HO.

BMJ. 2009 Sep 24;339:b3601. doi: 10.1136/bmj.b3601. No abstract available.

PMID:
19778971
6.

Prostate-specific antigen testing and prostate cancer screening.

Djavan B, Eckersberger E, Finkelstein J, Sadri H, Taneja SS, Lepor H.

Prim Care. 2010 Sep;37(3):441-59, vii. doi: 10.1016/j.pop.2010.05.001. Review.

PMID:
20705192
7.

To screen or nor to screen: the prostate cancer dilemma.

Stone NN, Crawford ED.

Asian J Androl. 2015 Jan-Feb;17(1):44-5. doi: 10.4103/1008-682X.142770.

8.

Stats & Facts. Prostate-specific antigen screening.

[No authors listed]

Manag Care Interface. 2001 Jul;14(7):40-1. No abstract available.

PMID:
11481814
9.

Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

Noordzij MA, Blanker MH.

J Natl Cancer Inst. 2015 Apr 16;107(6):djv110. doi: 10.1093/jnci/djv110. Print 2015 Jun. No abstract available.

PMID:
25888716
10.

Response.

Heijnsdijk EA, de Koning HJ.

J Natl Cancer Inst. 2015 Apr 16;107(6):djv111. doi: 10.1093/jnci/djv111. Print 2015 Jun. No abstract available.

PMID:
25888717
11.

Prostate specific antigen for detecting early prostate cancer.

Ilic D, Green S.

BMJ. 2009 Sep 24;339:b3572. doi: 10.1136/bmj.b3572. No abstract available.

PMID:
19778970
12.

Simulation optimization of PSA-threshold based prostate cancer screening policies.

Underwood DJ, Zhang J, Denton BT, Shah ND, Inman BA.

Health Care Manag Sci. 2012 Dec;15(4):293-309.

13.

Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : analysis of trends over time.

Haines IE.

Cancer. 2013 Mar 1;119(5):1113. doi: 10.1002/cncr.27876. Epub 2012 Oct 23. No abstract available.

14.

Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : analysis of trends over time.

Scosyrev E, Messing EM.

Cancer. 2013 Mar 1;119(5):1113-4. doi: 10.1002/cncr.27875. Epub 2012 Oct 23. No abstract available.

15.

Prostate-specific antigen screening for prostate cancer in older men in the United States of America.

Black A, Berg CD.

Gerontology. 2012;58(4):331-6. doi: 10.1159/000334242. Epub 2012 Feb 16.

PMID:
22343605
16.

Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time.

Bhatnagar V, Stewart ST, Bonney WW, Kaplan RM.

Urology. 2004 Jan;63(1):103-9.

PMID:
14751359
17.

Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.

Committee for Establishment of the Guidelines on Screening for Prostate Cancer; Japanese Urological Association.

Int J Urol. 2010 Oct;17(10):830-8. doi: 10.1111/j.1442-2042.2010.02613.x.

PMID:
20825509
18.

Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.

Braillon A, Dubois G.

J Natl Cancer Inst. 2012 May 16;104(10):793; author reply 793-4. doi: 10.1093/jnci/djs205. Epub 2012 Apr 5. No abstract available.

19.

False-positive screening results in the Finnish prostate cancer screening trial.

Kilpeläinen TP, Tammela TL, Määttänen L, Kujala P, Stenman UH, Ala-Opas M, Murtola TJ, Auvinen A.

Br J Cancer. 2010 Feb 2;102(3):469-74. doi: 10.1038/sj.bjc.6605512. Epub 2010 Jan 5.

20.

Clinical decisions. Prostate cancer screening--polling results.

Colbert JA, Adler JN.

N Engl J Med. 2012 Oct 25;367(17):e25. doi: 10.1056/NEJMclde1212034. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk